abs93.txt	objective		oncolytic	immunotherapy	involves	the	use	of	viruses	to	target	anddestroy	cancer	cells	and	to	induce	immune	responses	for	an	enhanced	antitumoreffect		talimogene	laherparepvec		a	genetically	modified	herpes	simplex	virustype	1	(hsv-1)	that	selectively	replicates	in	tumors	to	induce	lytic	cell	death	tumor	antigen	release		and	the	local	production	of	granulocyte-macrophagecolony-stimulating	factor	(gm-csf)		has	been	approved	for	the	treatment	of	adefined	population	of	patients	with	metastatic	melanoma		talimogene	laherparepvecis	administered	as	a	series	of	intralesional	injections		and	specific	proceduresare	implemented	to	minimize	the	risk	of	viral	exposure		because	talimogenelaherparepvec	represents	a	novel	therapeutic	modality		its	preparation	administration		and	handling	requirements	differ	from	current	therapies	pharmacists	have	an	important	role	in	developing	new	procedures	to	incorporate	itinto	clinical	practice		methods		in	this	review		pharmacists	with	experiencedispensing	talimogene	laherparepvec		in	the	clinical	trial	setting	and/or	as	acommercially	available	product	at	us	academic	institutions		synthesized	theirpersonal	experiences	through	group	discussions	to	provide	insights	on	theordering		receipt		storage		preparation		administration		and	handling	oftalimogene	laherparepvec		results		suggestions	for	patient	education	andpractical	guidance	to	assist	hospital	pharmacists	and	decision	makers	withimplementing	talimogene	laherparepvec	at	their	institutions	are	provided	conclusion		these	insights	may	further	inform	the	development	of	policies	orprocedures	to	incorporate	talimogene	laherparepvec	into	clinical	settings	andimprove	patient	outcomes	
